1 – 29 Psychotropics are often prescribed to control neuropsychiatric behavioral disturbances in these diseases. Aggression, agitation, anxiety, apathy, depression, disinhibition, and psychosis are among the many behavioral complications in neurodegenerative diseases, are highly prevalent, and add tremendously to patient distress and caregiver burden. Neuropsychiatric conditions abound in these neurodegenerative diseases, and psychotropic drugs are routinely applied in treating them. N eurodegenerative diseases are assuming increasing importance over time and have been classified into families, for example tauopathies characterized by aberrant tau protein (e.g., Alzheimer’s disease, Pick’s disease, progressive supranuclear palsy, corticobasal degeneration), synucleinopathies (e.g., Parkinson’s disease, dementia with Lewy bodies, multiple system atrophies), amyloidopathies (e.g., Alzheimer’s disease, Down’s syndrome), etc. Part I appeared in the Winter 2010 issue of The Journal of Neuropsychiatry and Clinical Neurosciences, available at. This report is the second of a two-part series on psychopharmacological neuroprotection in neurodegenerative disease.
0 kommentar(er)
